The company focuses on the field of chemically synthesized peptide injections. The core product, Thymus Method for Injection, has a large market share in its market segment and has abundant reserve products, and fund-raising projects will ease the company's production capacity bottlenecks. The company's 2012-2013 EPS is estimated to be 0.75 yuan and 0.98 yuan respectively. According to the 2012 25-30 times valuation, the recommended inquiry range is 18.8 yuan to 22.5 yuan.
【长江证券】双成药业:专注合成肽领域的优势企业
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.